{
  "id": 15596407,
  "title": "TriGemX Bio is going public through SPAC to get its migraine prospect to market",
  "url": "https://urgent.news/2026/10/19/trigemx-bio-is-going-public-through-spac-to-get-its-migraine-prospect",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-19T11:00:09.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/trigemx-bio-will-go-public-through-spac-to-get-its-migraine-prospect-to-market/"
  },
  "original_language": "en",
  "account": null,
  "summary": "The stock market will soon welcome another drug developer through a backdoor route that has been fallen out of favor now that traditional IPOs are flowing. TriGemX Bio, formerly known as Kallyope, is going public ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Seeking Alpha News",
        "title": "TriGemX Bio to go public in $600M TCGX merger",
        "url": "https://urgent.news/2026/10/19/trigemx-bio-to-go-public-in-600m-tcgx-merger",
        "published": "2026-10-19T11:18:25.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}